Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada

European Journal of Cancer

Volumn 48, Issue 13, 2012, Pages 1969-1976

  Hedden, Lindsay ^a,b   Kennecke, Hagen ^c   Villa, Diego ^c   Johnston, Karrisa ^d   Speers, Caroline ^c   Kovacic, Laurel ^c   Renouf, Daniel J ^c   Peacock, Stuart ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d ICON PLC   (United Kingdom)

Author keywords

Bevacizumab; Colorectal cancer; Cost effectiveness; First line treatment; Health economics; Second line treatment

Indexed keywords

BEVACIZUMAB;

AGED; AMBULATORY CARE; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HIDDEN MARKOV MODEL; HOSPITAL PATIENT; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SURVIVAL TIME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRITISH COLUMBIA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY;

EID: 84862151118     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.012     Document Type: Article

References (23)

1. Canadian Cancer Society Canadian Cancer Statistics 2009 2009 Canadian Cancer Society & National Cancer Institute of Canada Toronto, Ontario
2. J. Cassidy, S. Clarke, and E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 12 2008 2006 2012
3. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345 (Pubitemid 38944402)
4. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30 (Pubitemid 41095110)
5. C. Kelly, and J. Cassidy Chemotherapy in metastatic colorectal cancer Surg Oncol 16 1 2007 65 70 (Pubitemid 46880340)
6. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 9582 2007 135 142 (Pubitemid 47042893)
7. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237 (Pubitemid 41095086)
8. Roche Canada Product Monograph: Avastin 2005 Hoffman-La Roche Limited Mississauga, Ontario
9. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
10. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
11. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
12. F.F. Kabbinavar, J. Schulz, and M. McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 16 2005 3697 3705
13. A.D. Wagner Anti-angiogenic therapies for metastatic colorectal cancer Cochrane Database Syst Rev 3 2009 CD005392
14. H. Canada Authorization with Conditions of AVASTIN® (bevacizumab) 2005 Health Canada Ottawa, Ontario
15. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer: NICE technology appriasal guidance 118. National Institute for Health and Clinical Effectiveness: London, UK; 2007.
16. D. Renouf, H. Lim, and C. Speers Survival for metastatic colorectal cancer in the Bevacizumab Era: a population based analysis Clin Colorect Cancer 10 2 2011 97 101
17. Health Employers Association of British Columbia (HEABC). Collective agreements. Available from: < http://www.heabc.bc.ca/Page20.aspx >;2009 [cited 2009 April 22].
18. The Ontario Guide to Case Costing (Version 7.0). Ontario Ministry of Health and Long Term Care. Available from: < http://www.cancerriskmgmt.ca/ cancer-models-test/colorectal-cancer >; 2009 [accessed 20 July 2010].
19. B.P. Will, J.M. Berthelot, K.M. Nobrega, W. Flanagan, and W.K. Evans Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions Eur J Cancer 37 2001 1797 1804 (Pubitemid 32817055)
20. Canadian Agency for Drugs and Technologies in Health (CADTH) Guidelines for the economic evaluation of health technologies: Canada 3rd Ed. 2006 Canadian Agency for Drugs and Technologies in Health Ottawa
21. N. Mittmann, W.K. Evans, and A. Rocchi Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies Specific Guidance for Oncology Products 2009 Canadian Agency for Drugs and Technologies in Health Ottawa
22. R.M. Ness Outcome states of colorectal cancer: identification and description using patient focus groups Am J Gastroenterol 93 9 1998 1491 1497 (Pubitemid 29075188)
23. R.M. Ness Utility valuations for outcome states of colorectal cancer Am J Gastroenterol 94 6 1999 1650 1657 (Pubitemid 29260460)